PD-1 Antibody Sintilimab Combined With Capecitabine as Adjuvant Therapy for High-Risk Nasopharyngeal Carcinoma

NCT06900218 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

664

Enrollment

OTHER

Sponsor class

Conditions

Nasopharyngeal Carcinoma (NPC)

Interventions

DRUG: Sintilimab
DRUG: Capecitabine

Sponsor

Sun Yat-sen University